Table 2.
Mental health characteristics among participants enrolled in ATAHC with available mental health assessments at enrolment*
| Total study population |
Treated | Untreated HCV RNA positive at enrolment |
Untreated HCV RNA positive at enrolment |
|
|---|---|---|---|---|
| Mental health parameters/DASS-21 | n= 158 | n= 108 | n= 34 | n= 16 |
| Depression, median (range) | 8 (0–42) | 6 (0–42) | 13 (0–40) | 14 (0–36) |
| Normal, n (%) | 81 (51%) | 64 (59%) | 11 (32%) | 6 (37%) |
| Mild, n (%) | 20 (13%) | 12 (11%) | 6 (18%) | 2 (12%) |
| Moderate, n (%) | 28 (18%) | 18 (17%) | 9 (26%) | 1 (6%) |
| Severe, n (%) | 12 (8%) | 4 (4%) | 4 (12%) | 4 (25%) |
| Extremely severe, n (%) | 17 (11%) | 10 (9%) | 4 (12%) | 3 (19%) |
| Anxiety, median (range) | 6 (0–40) | 6 (0–40) | 10 (0–26) | 11 (0–40) |
| Normal, n (%) | 81 (51%) | 62 (57%) | 12 (35%) | 7 (44%) |
| Mild, n (%) | 13 (8%) | 9 (8%) | 3 (9%) | 1 (6%) |
| Moderate, n (%) | 34 (22%) | 22 (20%) | 8 (24%) | 4 (25%) |
| Severe, n (%) | 15 (9%) | 9 (8%) | 6 (18%) | 0 (0%) |
| Extremely severe, n (%) | 15 (9%) | 6 (6%) | 5 (15%) | 4 (25%) |
| Stress, median (range) | 12 (0–42) | 10 (0–42) | 14 (0–36) | 15 (0–38) |
| Normal, n (%) | 99 (63%) | 73 (68%) | 18 (53%) | 8 (50%) |
| Mild, n (%) | 21(13%) | 13 (12%) | 6 (17%) | 2 (12%) |
| Moderate, n (%) | 17 (11%) | 13 (12%) | 3 (9%) | 1 (6%) |
| Severe, n (%) | 12 (8%) | 5 (5%) | 4 (12%) | 3 (19%) |
| Extremely severe, n (%) | 9 (6%) | 4 (4%) | 3 (9%) | 2 (12%) |
| Mental health parameters/ MINI | n= 160 | n= 110 | n= 34 | n= 16 |
| Current major depressive episode, n (%) | 25 (16%) | 10 (9%) | 9 (26%) | 6 (37%) |
| Suicide risk (moderate and high), n (%) | 28 (18%) | 11 (10%) | 12 (35%) | 5 (31%) |
| Psychiatric medication- total, n (%)¶ | 49 (30%) | 31 (28%) | 12 (35%) | 6 (33%) |
| Antidepressants- total, n (%)¶ | 37 (23%) | 23 (21%) | 8 (24%) | 6 (33%) |
*
total n=158 for DASS-21 & total n=160 for MINI,
¶
some participants take more than one type of medication